Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced new interim data from its clinical studies of tumor-infiltrating lymphocyte, or TIL, therapy LN-145 in patients with advanced cervical cancer, which showed an objective response rate, or ORR, of 44 percent, and a disease control rate of 89 percent. Merck & Co., Inc. (NYSE: MRK)'s Keytruda, which was used as a reference, had a 14 percent ORR. Meanwhile, updated results from Cohort 2 in the ongoing innovaTIL-01 study of lifileucel in advanced melanoma showed an ORR of 38 percent and a disease control rate of 76 percent. The stock advanced 19.77 percent to $13.45 in after-hours trading. yahoo finance
